Prostate News and Research

RSS

Aspirin may modestly reduce cancer risk

A daily dose of adult-strength aspirin may modestly reduce cancer risk in populations with high rates of colorectal, prostate, and breast cancer if taken for at least five years.

18 Apr 2007

Immunomedics presents results on novel immunotoxin for prostate and lung cancers

Immunomedics has presented at the 2007 Annual Meeting of the American Association for Cancer Research results on the in vitro and in vivo evaluation of a novel immunotoxin, Rap-hRS7, for the potential treatment of prostate and lung cancers.

18 Apr 2007

Scientists tackle cancer with different approaches

Studies presented at the 2007 meeting of the American Association for Cancer Research show how researchers are using the new, as well as the natural, to help design and test new drugs to treat cancer.

18 Apr 2007

Cell Genesys reports data from clinical trials of GVAX immunotherapy for prostate cancer

Evaluation of antibody responses in patients with advanced prostate cancer from these studies shows that the GVAX cell-based immunotherapy induces antibody responses to a broad array of prostate cancer- associated antigens, including some not previously known to be associated with prostate cancer.

18 Apr 2007

Clioquinol shows promise in fighting cancer

Researchers from the Barbara Ann Karmanos Cancer Institute in Detroit, MI presented strong evidence today that an antibiotic typically prescribed for Alzheimer's patients could be effective in eventually treating certain types of cancers.

18 Apr 2007

Anti-anemia drug darbepoetin alfa no better than placebo for cancer patients

Results from a phase III drug trial indicate that an anti-anemia drug did not significantly decrease the need for blood transfusions in patients not on chemotherapy, and decreased overall patient survival when compared to placebo, according to researchers from the UCLA Medical Center at the 2007 Annual Meeting of the American Association for Cancer Research.

17 Apr 2007

Selenium as therapy for prostate cancer

Selenium may offer an intervention strategy for the treatment of prostate cancer according to results of a study from the laboratory of Allen Gao, PhD, which will be presented by Yan Hu, PhD, Departments of Medicine and Pharmacology and Therapeutics, Roswell Park Cancer Institute (RPCI) at the 2007 centennial meeting of the American Association for Cancer Research (AACR), April 14-18, in Los Angeles, CA.

17 Apr 2007

Side-effects of treatment for localized prostate cancer

It seems plausible that prostate cancer (CaP) patients might value health states associated with side-effects of treatment for localized CaP as less detrimental than men with no CaP.

17 Apr 2007

Lilly and AACR tackle cancer together

Innovative and collaborative cancer research can be the catalyst to improving patient outcomes.

17 Apr 2007

FDA accepts Satraplatin NDA for priority review

Spectrum Pharmaceuticals has announced that the New Drug Application (NDA) for satraplatin has been accepted for priority review by the U.S. Food & Drug Administration (FDA).

17 Apr 2007

FDA accepts GPC Biotech's Satraplatin NDA

GPC Biotech AG has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for satraplatin in combination with prednisone for patients with hormone-refractory prostate cancer (HRPC) whose prior chemotherapy has failed.

17 Apr 2007

Biomira selects PX-866 as clinical development candidate

Biomira Inc. has announced that it has selected PX-866 as its next clinical development candidate.

17 Apr 2007

Snake venom toxin as a treatment for prostate cancer

This certainly sounds unusual, but Dr. Son and colleagues report on the effectiveness of the snake venom toxin (SVT) Vipera lebetina turanica in the inhibition of androgen-independent prostate cancer (AICAP) in the February 2007 issue of Molecular Cancer Therapeutics .

16 Apr 2007

Report on radical prostatectomy for octogenarians

There is no defined recommendation for when to stop prostate cancer (CaP) screening, except when the life expectancy decreases to less than 10 years.

16 Apr 2007

Functional diffusion map measures effectiveness of treatment for prostate cancer

Researchers at the University of Michigan Comprehensive Cancer Center have identified a new imaging technique that can measure the effectiveness of treatment for prostate cancer that has spread to the bones.

16 Apr 2007

New diagnostic technologies to predict and monitor cancer risks

Molecular messages and signals circulating in blood or contained in cells lining the airway can identify early stage cancer, according to research reported at the 2007 Annual Meeting of the American Association for Cancer Research.

16 Apr 2007

Health disparities in access to healthcare

Minority individuals are much more likely to develop and die from cancer than the general U.S. population.

16 Apr 2007

Eating well still one of the best ways to prevent cancer and promote good health

We all know that eating fruits, vegetables and soy products provides essential nutrition for a healthy lifestyle, while obesity leads to the opposite.

16 Apr 2007

Low serum testosterone levels independently associated with fall risk in elderly men

Prolonged hypogonadism may result in erectile dysfunction, decreased libido, anemia, sarcopenia, memory loss, bone mineral loss, and the metabolic syndrome.

15 Apr 2007

Lower educational level makes some men more vulnerable to the effects of prostate cancer

Among men who have received similar treatments for prostate cancer, those with less education , particularly those who did not graduate from high school , experience a significant drop in their quality of life after treatment compared with men who have more education, according to a study led by researchers at the San Francisco VA Medical Center (SFVAMC).

15 Apr 2007